SCHEMBL16017553

SCHEMBL16017553

CC(C)(C)c1cnc(O)c(NS(=O)(=O)c2cccc(C(=O)O)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ PTK2B Q14289 1/20 0.52
▸ KMT2A Q03164 3/20 0.51
▸ MAPT P10636 1/20 0.48
▸ ERAP1 Q9NZ08 1/20 0.48
▸ ACLY P53396 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47
▸ MEN1 O00255 1/20 0.46
▸ AKR1C3 P42330 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ TDP1 Q9NUW8 1/20 0.44
▸ PIK3C2B O00750 1/20 0.44
▸ PIK3C2G O75747 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16017558 0.88 KDM4E (0.57) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL13975457 0.86 ACLY (0.53) KDM4ETSHRPTK2BKMT2AERAP1
SCHEMBL16020314 0.85 KDM4E (0.55) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL16017555 0.83 KDM4E (0.47) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL19558648 0.82 KDM4E (0.52) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL18136984 0.82 KDM4E (0.52) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL16017543 0.79 AKR1C3 (0.53) KDM4ETSHRPTK2BKMT2AMAPT
SCHEMBL13975453 0.77 SLC40A1 (0.55) TSHRKMT2AACLYMEN1ALDH1A1
SCHEMBL24139842 0.76 ALDH1A1 (0.50) KDM4ETSHRPTK2BKMT2AERAP1
SCHEMBL16235212 0.73 SLC40A1 (0.58) KDM4ETSHRPTK2BKMT2AACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9808466-B2 Macrocyclic compounds as protein kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 2017-11-07 — — US disclosed
US-9808466-B2 Macrocyclic compounds as protein kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 2017-11-07 — — US disclosed
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2016-10-13 — — US disclosed
US-9284334-B2 Macrocyclic compounds as protein kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2016-03-15 — — US disclosed
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 KDM4E 613/4885TSHR 1618/4885PTK2B 203/4885
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 KDM4E 613/4885TSHR 1618/4885PTK2B 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback